Monograph Details
|
|
Central Nervous System
> Mood disorders
|
|
TOFRANIL-PM |
| Manufacturer |
|
Mallinckrodt, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Tricyclic. |
| Generic Name |
|
Imipramine pamoate (equal to HCl) 75 mg, 100 mg, 125 mg, 150 mg; caps. |
| Also |
|
• TOFRANIL
|
| Indications |
|
Depression. |
| Children |
|
Not recommended. |
| Adults |
|
Outpatients: initially 75mg/day; max 200mg/day. Inpatients: initially 100–150mg/day, max 300mg/day. Adolescents or elderly: start with Tofranil 25–50mg/day; usual max 100mg/day. For maintenance doses >75mg, may substitute Tofranil-PM for divided or bedtime dosing. |
| Contraindications |
|
During or within 14 days of MAOIs. Acute post-MI. |
| Precautions |
|
Urinary retention. Glaucoma. Cardiovascular disease. Epilepsy. Suicidal tendencies. ECT. Psychosis. Mania/hypomania. Bipolar disorder. Diabetes. Hyperthyroidism. Renal or hepatic disorders. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Hyperpyretic crisis, convulsions, death with MAOIs. Potentiates alcohol, sympathomimetics, CNS depressants. Potentiated by methylphenidate, CYP2D6 inhibitors; monitor plasma levels with cimetidine, SSRIs, phenothiazines, type 1C antiarrhythmics (eg, quinidine). Antagonized by barbiturates, carbamazepine, phenytoin. Paralytic ileus, hyperpyrexia with anticholinergics. Increased cardiovascular effects with methylphenidate. Blocks guanethidine, clonidine. |
| Adverse Reactions |
|
Drowsiness, anticholinergic effects, CNS overstimulation, arrhythmias, extrapyramidal symptoms, hypo- or hypertension, nausea, fatigue, rash, increased perspiration, headache, changes in blood sugar, photosensitivity, edema, blood dyscrasias (discontinue if occurs), jaundice. |
| How Supplied |
Tabs—100
Caps—30, 100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
